share_log

10-Q: Q2 2024 Earnings Report

10-Q: Q2 2024 Earnings Report

10-Q:2024財年二季報
美股SEC公告 ·  08/14 10:34
Moomoo AI 已提取核心訊息
60 Degrees Pharmaceuticals, Inc. reported its financial performance for the quarter ended June 30, 2024, with a significant increase in product revenues, primarily driven by domestic sales of its malaria prevention drug, Arakoda. Product revenues reached $124,972, a 109.92% increase from the previous year's quarter, while service revenues remained at zero. The cost of revenues decreased by 51.32% to $89,564, resulting in a gross profit of $35,408, marking a substantial improvement from the prior year's gross loss. Research revenues were minimal at $728. Operating expenses saw a sharp rise, with research and development costs at $3,095,326, mainly due to expenses related to the planned babesiosis trial for tafenoquine and a significant expense recognized upon delivery of a report from Kentucky Technology, Inc. General and administrative expenses also increased...Show More
60 Degrees Pharmaceuticals, Inc. reported its financial performance for the quarter ended June 30, 2024, with a significant increase in product revenues, primarily driven by domestic sales of its malaria prevention drug, Arakoda. Product revenues reached $124,972, a 109.92% increase from the previous year's quarter, while service revenues remained at zero. The cost of revenues decreased by 51.32% to $89,564, resulting in a gross profit of $35,408, marking a substantial improvement from the prior year's gross loss. Research revenues were minimal at $728. Operating expenses saw a sharp rise, with research and development costs at $3,095,326, mainly due to expenses related to the planned babesiosis trial for tafenoquine and a significant expense recognized upon delivery of a report from Kentucky Technology, Inc. General and administrative expenses also increased to $1,129,560, reflecting higher compensation and related expenses. The company reported a net loss of $4,172,755, attributed to 60 Degrees Pharmaceuticals, Inc., which included a minor loss from the change in fair value of derivative liabilities and a small amount of other net income. The company's cash used in operating activities was $2,328,650 for the six months ended June 30, 2024. The report also highlighted a reverse stock split effective August 12, 2024, and the sale of 677,819 shares under an At-the-Market Issuance Sales Agreement, generating proceeds of $1,994,583. The company's financial statements have been prepared on a going concern basis, despite not having demonstrated the ability to generate enough revenues to cover operating expenses to date.
60度藥業公佈了截至2024年6月30日的季度財務績效報告,產品收入顯著增長,主要受到其瘧疾預防藥物Arakoda國內銷售的推動。產品收入達到124,972美元,較上年同期增長109.92%,而服務收入仍爲零。成本費用降低了51.32%,爲89,564美元,毛利潤爲35,408美元,較去年同期的毛利虧損有了顯着改善。研究收入僅爲728美元。營業費用大幅上升,其中研發費用爲3,095,326美元,主要是由於與蚤病試驗計劃相關的費用和從Kentucky Technology,Inc獲得報告的顯着費用。總部和行政費用也增加至1,129,560美元,反映出更高的薪酬和相關費用。公司報告淨虧損4,172...展開全部
60度藥業公佈了截至2024年6月30日的季度財務績效報告,產品收入顯著增長,主要受到其瘧疾預防藥物Arakoda國內銷售的推動。產品收入達到124,972美元,較上年同期增長109.92%,而服務收入仍爲零。成本費用降低了51.32%,爲89,564美元,毛利潤爲35,408美元,較去年同期的毛利虧損有了顯着改善。研究收入僅爲728美元。營業費用大幅上升,其中研發費用爲3,095,326美元,主要是由於與蚤病試驗計劃相關的費用和從Kentucky Technology,Inc獲得報告的顯着費用。總部和行政費用也增加至1,129,560美元,反映出更高的薪酬和相關費用。公司報告淨虧損4,172,755美元,歸屬於60度製藥公司,其中包括因衍生性負債公平價值變動的小的虧損和少量其他淨收入。截至2024年6月30日,公司的運營活動現金流量爲-2,328,650美元。報告還強調了自2024年8月12日起生效的股票拆分以及在「按市場發行銷售協議」下出售了677,819股股份,共計獲得1,994,583美元。儘管迄今尚未表現出足夠的收入來支付營業費用,但公司的財務報表已基於持續營業的基礎進行編制。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息